Gaucher disease

View All

pharma-news
Avrobio taps Magenta’s ADC; Eli Lilly ramps up; FDA postpones decision; CSL gears up to fight pandemic,

Avrobio taps ADC of Magenta for enhancing gene therapy conditioning Avrobio is working to make conditioning safer. The company is collaborating with Magenta Therapeutics to check antibody-drug conjugate. Under the agreement, the partners will evaluate Magenta’s lead conditioning program, MGTA-117, with at lea...

Find More

Gaucher disease Market
Gaucher disease Market Analysis: Rich Pipeline Drives the Market Ahead

Gaucher Disease Market is anticipated to enhance in the forecast period owing to a strong Gaucher disease pipeline. According to the National Organization of Rare Diseases, Gaucher disease is a rare, inherited, metabolic disorder, which is characterized by an accumulation of harmful fats, chiefly the glycolipid ...

Find More

Gaucher Disease
Gaucher Disease: “Rare Disorder with High Unmet Needs”

Gaucher Disease is a rare autosomal recessive inherited multisystem disease with phenotypic variation from mild to very severe. It is the most common lysosomal storage disorder which occurs due to the deficiency of an enzyme β-glucocerebrosidase that helps in degrading glucocerebroside into glucose and ceramide. Lac...

Find More

Rising of Orphan Drug Development

Introduction: Any disease that affects less than 200,000 patients or 1 in 1500 is termed as a rare disease. There are around 5000 to 8000 rare disease reported, out which only 10% have cure. According to the European Organization for rare disease, 80% of rare diseases are genetic in nature. Some of the rare disease...

Find More